drugset
drugset / Trial / NCT03518463

Enhanced Recovery After Surgery for Emergency Caesarean Deliveries

NCT03518463 ↗

Completed 160 enrolled Mbarara University of Science and Technology
RandomizedParallel-groupDouble-blindTreatment

Summary

Caesarean section (CS) constitutes a large proportion of the total surgical volume in low-income countries. This rate comes with challenges including surgical complications, shortage of beds, and consequently long waiting time for operations and high costs. These have led to the adoption of ERAS in developed countries in a bid to save costs by reducing hospital length of stay without compromising the health of the mother and her baby.

Timeline

Start
2017-06-20
Primary completion
2017-07-30
Completion
2017-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetaminophen Small molecule 500 mg —
Subject Amoxicillin-clavulunate Unknown 850 mg Oral
Subject Bupivacaine Other / unclassified 2 mg/kg Intrathecal
Subject Bupivacaine Other / unclassified 10 mg Intrathecal
Subject Bupivacaine Other / unclassified 15 mg Intrathecal
Subject Cefazolin Small molecule 1 g Intravenous
Subject Ceftriaxone Other / unclassified 2 g Intravenous
Subject Dexamethasone Small molecule 8 mg Intravenous
Subject Diclofenac Other / unclassified 100 mg Rectal
Subject Epinephrine Other / unclassified 100 ug —
Subject Ibuprofen Small molecule 400 mg —
Subject Metoclopromide Unknown 10 mg Intravenous
Subject Misoprostol Other / unclassified 400 ug Rectal
Subject Morphine Other / unclassified 100 ug Intrathecal
Subject Ranitidine Unknown 150 mg Intravenous
Subject ampiclox Unknown 2 g Intravenous

Indications

pregnancy disorder